Inhibikase Therapeutics, Inc.
IKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001750149
No open-market purchases or sales by Inhibikase Therapeutics, Inc. insiders were filed in the last 90 days; 105 institutions reported holding it in 13F filings for Q2 2026, worth $239.2M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Inhibikase Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 14 | 21 | +7 |
| Shares | 3.79M | 4.10M | +303.7K (+8.0%) |
| Value | $10.6M | $7.78M | −$2.84M (−26.7%) |
New holders (9)
Institutions that held Inhibikase Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 101,278 | $192.0K | 0.00% |
| Bank of New York Mellon Corp | 39,580 | $75.0K | 0.00% |
| Goldman Sachs Group Inc | 27,895 | $53.0K | 0.00% |
| Geode Capital Management, LLC | 25,833 | $49.0K | 0.00% |
| Shay Capital LLC | 20,000 | $38.0K | 0.01% |
| Northern Trust Corp | 15,714 | $30.0K | 0.00% |
| Envestnet Asset Management Inc | 10,988 | $21.0K | 0.00% |
| UBS Group AG | 8,548 | $16.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 5,406 | $10.0K | 0.00% |
Sold out (2)
Institutions that held Inhibikase Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Altium Capital Management LP | 109,749 | $307.0K |
| HRT Financial LP | 15,000 | $42.0K |